Psyence Biomedical Schedules Shareholder Meeting, Files Financials
Ticker: PBMWW · Form: 6-K · Filed: Oct 23, 2024 · CIK: 1985062
Sentiment: neutral
Topics: shareholder-meeting, financials, filing
Related Tickers: PSYG
TL;DR
Psyence Biomedical (PSYG) holding shareholder meeting Nov 12, releasing 2023/2024 financials. Check it out.
AI Summary
Psyence Biomedical Ltd. has filed a Form 6-K, announcing its Annual General and Special Meeting of Shareholders scheduled for November 12, 2024. The filing also includes the company's Consolidated Financial Statements for the years ended March 31, 2024 and March 31, 2023.
Why It Matters
This filing provides shareholders with crucial information regarding the upcoming annual meeting and the company's financial performance, enabling informed voting and investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing announcing a shareholder meeting and providing financial statements, with no new material events or significant financial changes disclosed.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Registrant
- November 12, 2024 (date) — Annual General and Special Meeting date
- March 31, 2024 (date) — Fiscal year end for financial statements
- March 31, 2023 (date) — Fiscal year end for financial statements
FAQ
When is the Annual General and Special Meeting of Shareholders for Psyence Biomedical Ltd.?
The meeting is scheduled to be held on November 12, 2024.
What financial statements are included with this 6-K filing?
The filing includes the Consolidated Financial Statements of the Company for the years ended March 31, 2024 and March 31, 2023.
What is the purpose of the Management Information Circular mentioned in the filing?
The Management Information Circular is provided along with the Notice of Annual General and Special Meeting of Shareholders.
What is Psyence Biomedical Ltd.'s principal executive office address?
The address is 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
Does Psyence Biomedical Ltd. file annual reports under Form 20-F or Form 40-F?
Psyence Biomedical Ltd. files annual reports under Form 20-F, as indicated by the checkmark in the filing.
Filing Stats: 213 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-10-23 16:01:44
Filing Documents
- tm2426281-1_6k.htm (6-K) — 15KB
- tm2426281d1_exh99x1.htm (EX-99.1) — 1132KB
- tm2426281d1_exh99x2.htm (EX-99.2) — 11KB
- tm2426281d1_exh99x3.htm (EX-99.3) — 8KB
- ft_praxity-bwlr.jpg (GRAPHIC) — 11KB
- lg_mnp-bwlr.jpg (GRAPHIC) — 3KB
- lg_psycencebiomed-bwlr.jpg (GRAPHIC) — 20KB
- sg_mnpllp-bw.jpg (GRAPHIC) — 3KB
- px_24psyencepy01pg01-bw.jpg (GRAPHIC) — 316KB
- px_24psyencepy01pg02-bw.jpg (GRAPHIC) — 479KB
- 0001104659-24-110850.txt ( ) — 2287KB
From the Filing
tm2426281-1_6k - none - 1.578119s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant's name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBIT INDEX Exhibit Description 99.1 Notice of Annual General and Special Meeting of Shareholders to be held on November 12, 2024 and Management Information Circular, including the Consolidated Financial Statements of the Company for the years ended March 31, 2024 and 2023, and the Management Discussion and Analysis related thereto, dated October 23, 2024. 99.2 Notice of Meeting and Record Date 99.3 Form of Proxy SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: October 23, 2024 Psyence Biomedical Ltd. By: /s/ Dr. Neil Maresky Name:Dr. Neil Maresky Title: Chief Executive Officer and Director